{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:15:21Z","timestamp":1791850521377,"version":"4.3.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.kint.2024.05.033","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:53:04Z","timestamp":1721436784000},"page":"573-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Controversies and practical management of patients with gout and chronic kidney disease"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3312-8193","authenticated-orcid":false,"given":"Richard J.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Mandell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Mount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Botson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Ali","family":"Abdellatif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rhoades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2024.05.033_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.semarthrit.2012.09.009","article-title":"Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010","volume":"42","author":"Juraschek","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.kint.2024.05.033_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050046","article-title":"Reduced glomerular function and prevalence of gout: NHANES 2009-10","volume":"7","author":"Krishnan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2024.05.033_bib3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ndt\/gfu352","article-title":"Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study","volume":"30","author":"Jing","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.05.033_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2369-12-36","article-title":"Chronic kidney disease in gout in a managed care setting","volume":"12","author":"Fuldeore","year":"2011","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2024.05.033_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001015","article-title":"Failure to reach uric acid target of\u00a0<0.36 mmol\/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality","volume":"5","author":"Perez Ruiz","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.kint.2024.05.033_bib6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/ckj\/sfz136","article-title":"Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study","volume":"14","author":"Kielstein","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2024.05.033_bib7","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1111\/bcp.13738","article-title":"Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort","volume":"84","author":"Laville","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.kint.2024.05.033_bib8","first-page":"3204","article-title":"Systemic urate deposition: an unrecognized complication of gout?","volume":"9","author":"Khanna","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.kint.2024.05.033_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1053\/j.ajkd.2006.08.019","article-title":"J-shaped mortality relationship for uric acid in CKD","volume":"48","author":"Suliman","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.033_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13075-021-02416-y","article-title":"Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review","volume":"23","author":"Pisaniello","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.kint.2024.05.033_bib11","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.05.033_bib12","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.05.033_bib13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40261-014-0238-6","article-title":"Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease","volume":"34","author":"Wason","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.kint.2024.05.033_bib14","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2024.05.033_bib16","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2024.05.033_bib17","first-page":"CD006190","article-title":"Colchicine for acute gout","volume":"8","author":"McKenzie","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2024.05.033_bib18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3899\/jrheum.170137","article-title":"Corticosteroid or nonsteroidal antiinflammatory drugs for the treatment of acute gout: a systematic review of randomized controlled trials","volume":"45","author":"Billy","year":"2018","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.kint.2024.05.033_bib19","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.41699","article-title":"A\u00a0randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares","volume":"73","author":"Saag","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2024.05.033_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jbspin.2012.09.009","article-title":"ACTH as first line treatment for acute gout in 181 hospitalized patients","volume":"80","author":"Daoussis","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.kint.2024.05.033_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.kint.2024.05.033_bib22","article-title":"Effectiveness and safety of anakinra in gouty arthritis: a case series and review of the literature","volume":"9","author":"Jeria-Navarro","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.kint.2024.05.033_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10787-020-00753-z","article-title":"Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis","volume":"29","author":"Jena","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.kint.2024.05.033_bib24","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.kint.2024.05.033_bib25","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials","volume":"32","author":"Wortmann","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.kint.2024.05.033_bib26","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/ard-2023-224731","article-title":"Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial","volume":"82","author":"Stamp","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2024.05.033_bib27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2024.05.033_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease","volume":"135","author":"Robinson","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.kint.2024.05.033_bib29","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3899\/jrheum.131226","article-title":"Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study","volume":"41","author":"Sundy","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.kint.2024.05.033_bib30","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2024.05.033_bib31","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/ndt\/gfr223","article-title":"Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease","volume":"27","author":"Brymora","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.05.033_bib32","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/art.21105","article-title":"The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial","volume":"52","author":"Huang","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2024.05.033_bib33","doi-asserted-by":"crossref","first-page":"d8190","DOI":"10.1136\/bmj.d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study","volume":"344","author":"Choi","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.kint.2024.05.033_bib34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13098-023-01182-y","article-title":"Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"15","author":"You","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.kint.2024.05.033_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.35353","article-title":"Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan","volume":"4","author":"Chung","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.kint.2024.05.033_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.30885","article-title":"Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.kint.2024.05.033_bib37","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.kint.2024.05.033_bib38","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2024.05.033_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101501","article-title":"Allopurinol hypersensitivity: pathogenesis and prevention","volume":"34","author":"Stamp","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.kint.2024.05.033_bib40","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrrheum.2013.20","article-title":"Crystal arthritis: is HLAB genotyping the future of gout pharmacogenomics?","volume":"9","author":"Singh","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.kint.2024.05.033_bib41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00000441-198610000-00006","article-title":"Evaluation of a thiazide-allopurinol drug interaction","volume":"292","author":"Hande","year":"1986","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.kint.2024.05.033_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.kint.2024.05.033_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2024.05.033_bib44","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.semarthrit.2014.05.007","article-title":"Impaired response or insufficient dosage? Examining the potential causes of \u201cinadequate response\u201d to allopurinol in the treatment of gout","volume":"44","author":"Stamp","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.kint.2024.05.033_bib45","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2024.05.033_bib46","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","article-title":"Allopurinol dose escalation to achieve serum urate below 6 mg\/dL: an open-label extension study","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2024.05.033_bib47","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.05.033_bib49","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.kint.2024.05.033_bib50","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100028","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management","volume":"1","author":"O\u2019Dell","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.kint.2024.05.033_bib51","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.41638","article-title":"Reassessing the Cardiovascular Safety of Febuxostat: implications of the Febuxostat versus Allopurinol Streamlined Trial","volume":"73","author":"Choi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2024.05.033_bib52","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1002\/art.39769","article-title":"Febuxostat for patients with gout and severe chronic kidney disease: which is the appropriate dosage? Comment on the article by Saag et\u00a0al","volume":"68","author":"Quilis","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2024.05.033_bib53","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s40744-022-00480-7","article-title":"Febuxostat therapy for patients with gout and stage 2-4 CKD: a retrospective study","volume":"9","author":"Zhang","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.kint.2024.05.033_bib54","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3904\/kjim.2018.423","article-title":"Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis","volume":"35","author":"Kim","year":"2020","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.kint.2024.05.033_bib55","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1136\/annrheumdis-2020-218226","article-title":"Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland","volume":"81","author":"Quilis","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2024.05.033_bib56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s42358-019-0080-x","article-title":"Benzbromarone in the treatment of gout","volume":"59","author":"Azevedo","year":"2019","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.kint.2024.05.033_bib57","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ckj\/sfx036","article-title":"Lesinurad: what the nephrologist should know","volume":"10","author":"Sanchez-Nino","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2024.05.033_bib58","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.ASN.0000105320.04395.D0","article-title":"Clinical and molecular analysis of patients with renal hypouricemia in Japan\u2014influence of URAT1 gene on urinary urate excretion","volume":"15","author":"Ichida","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.033_bib59","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.semarthrit.2018.06.004","article-title":"Combination urate-lowering therapy in the treatment of gout: what is the evidence?","volume":"48","author":"Perez-Ruiz","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.kint.2024.05.033_bib60","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2024.05.033_bib61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.42335","article-title":"A\u00a0randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings","volume":"75","author":"Botson","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2024.05.033_bib62","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/art.41731","article-title":"Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 10","key":"10.1016\/j.kint.2024.05.033_bib63","article-title":"The impact of azathioprine on the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout [abstract]","volume":"72","author":"Baraf","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2024.05.033_bib64","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1681\/ASN.2021050598","article-title":"Effect of low-dose methotrexate on eGFR and kidney adverse events: a randomized clinical trial","volume":"32","author":"Sparks","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.033_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9056086","article-title":"A\u00a0rapidly fatal case of low-dose methotrexate toxicity","volume":"2018","author":"Shaikh","year":"2018","journal-title":"Case Rep Med"},{"key":"10.1016\/j.kint.2024.05.033_bib66","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0272-6386(12)80995-4","article-title":"Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases","volume":"23","author":"Ifudu","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.033_bib67","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.34067\/KID.0000000000000221","article-title":"Management of patients with gout and kidney disease: a review of available therapies and common missteps","volume":"4","author":"Kannuthurai","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.kint.2024.05.033_bib68","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1097\/RHU.0000000000001438","article-title":"Serum urate levels of hemodialyzed renal patients revisited","volume":"27","author":"Arenas","year":"2021","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.kint.2024.05.033_bib69","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/1756-185X.14334","article-title":"Urate-lowering therapy for patients with gout on hemodialysis","volume":"25","author":"Alkilany","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.kint.2024.05.033_bib70","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/j.1600-6143.2011.03613.x","article-title":"Association of serum uric acid with graft survival after kidney transplantation: a time-varying analysis","volume":"11","author":"Haririan","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2024.05.033_bib71","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1097\/TXD.0000000000001081","article-title":"New-onset gout as an independent risk factor for returning to dialysis after kidney transplantation","volume":"6","author":"Li","year":"2020","journal-title":"Transplant Direct"},{"key":"10.1016\/j.kint.2024.05.033_bib72","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jcpt.12794","article-title":"Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia","volume":"44","author":"Shen","year":"2019","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.kint.2024.05.033_bib73","doi-asserted-by":"crossref","first-page":"e614","DOI":"10.1097\/MJT.0000000000000044","article-title":"Colchicine-induced myopathy in a tacrolimus-treated renal transplant recipient: case report and literature review","volume":"23","author":"Yousuf Bhat","year":"2016","journal-title":"Am J Ther"},{"key":"10.1016\/j.kint.2024.05.033_bib74","article-title":"Pegloticase efficacy and safety in kidney transplant recipients: results of the phase IV, open-label PROTECT clinical trial","volume":"37","author":"Abdellatif","year":"2023","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2024.05.033_bib75","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13075-020-02260-6","article-title":"Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study","volume":"22","author":"Toprover","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.kint.2024.05.033_bib76","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jamacardio.2019.3201","article-title":"Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with gout","volume":"4","author":"Klauser","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.kint.2024.05.033_bib77","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.05.033_bib78","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.05.033_bib79","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.05.033_bib80","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.033_bib81","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00005792-196012000-00001","article-title":"The kidney in gout","volume":"39","author":"Talbott","year":"1960","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kint.2024.05.033_bib82","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1056\/NEJMe2015886","article-title":"Urate-lowering therapy and chronic kidney disease progression","volume":"382","author":"Feig","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824004733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824004733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T05:23:33Z","timestamp":1726723413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253824004733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0085253824004733"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2024.05.033","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies and practical management of patients with gout and chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}